Syndax Pharmaceuticals Inc [SNDX] stock is trading at $20.72, down -0.77%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The SNDX shares have gain 6.20% over the last week, with a monthly amount glided 24.67%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
BTIG Research reiterated its Buy rating and increased its price target to $56 on August 05, 2025. Goldman initiated its recommendation with a Buy and recommended $18 as its price target on July 10, 2025. UBS started tracking with a Buy rating for this stock on October 24, 2024, and assigned it a price target of $37. In a note dated June 28, 2024, Jefferies initiated a Buy rating and provided a target price of $37 on this stock.
Syndax Pharmaceuticals Inc [SNDX] stock has fluctuated between $8.58 and $21.22 over the past year. Currently, Wall Street analysts expect the stock to reach $33.75 within the next 12 months. Syndax Pharmaceuticals Inc [NASDAQ: SNDX] shares were valued at $20.72 at the most recent close of the market. An investor can expect a potential return of 62.89% based on the average SNDX price forecast.
Analyzing the SNDX fundamentals
Syndax Pharmaceuticals Inc [NASDAQ:SNDX] reported sales of 111.55M for the trailing twelve months, which represents a growth of 266.97%. Gross Profit Margin for this corporation currently stands at 0.95% with Operating Profit Margin at -2.75%, Pretax Profit Margin comes in at -2.79%, and Net Profit Margin reading is -2.79%. To continue investigating profitability, this company’s Return on Assets is posted at -0.56, Equity is -1.61 and Total Capital is -0.7. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of2.99.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 20.41 points at the first support level, and at 20.09 for the second support level. However, for the 1st resistance point, the stock is sitting at 21.23, and for the 2nd resistance point, it is at 21.74.
Ratios To Look Out For
For context, Syndax Pharmaceuticals Inc’s Current Ratio is 4.64. Also, the Quick Ratio is 4.42, while the Cash Ratio stands at 1.02. Considering the valuation of this stock, the price to sales ratio is 16.14, the price to book ratio is 15.60.
Transactions by insiders
Recent insider trading involved Metzger Michael A, Chief Executive Officer, that happened on Sep 08 ’25 when 0.16 million shares were sold. Director, MICHAEL METZGER completed a deal on Sep 08 ’25 to buy 0.16 million shares. Meanwhile, Director Podlesak Dennis sold 19200.0 shares on Aug 18 ’25.
